Brain tumor inflammation seen in real time with new imaging agent

NCT ID NCT07462507

First seen Jun 25, 2026 · Last updated Jun 25, 2026

Summary

This study is testing a new radioactive tracer called [C-11]-CS1P1 that lights up inflammation in brain tumors during a PET scan. Researchers will scan 104 adults with primary or secondary brain cancers before and after treatment to see how inflammation patterns change. The goal is to better understand the role of inflammation in these tumors and how it relates to MRI findings and patient outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

[C-11]-CS1P1 (a radioactive tracer for PET scans)

What this could lead to

If successful, this could help doctors better understand inflammation in brain tumors and improve how they monitor treatment response.

What could go wrong

This is an early-phase imaging study, not a treatment trial. It may not lead to direct patient benefits, and the tracer's usefulness in routine care is uncertain.

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) brain cancer central nervous system cancer glioblastoma glioma metastatic malignant neoplasm in the brain oligodendroglioma secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.